Effects of angiotensin-converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats

被引:12
|
作者
Zhang, RY
Wang, LF [1 ]
Zhang, L
Meng, XN
Li, SJ
Wang, WR
机构
[1] Harbin Med Coll, Clin Hosp 1, Dept Cardiol, Harbin 150001, Peoples R China
[2] Harbin Med Coll, Clin Hosp 1, Dept Pathol, Harbin 150001, Peoples R China
关键词
Smad; ventricular remodeling; angiotensin converting enzyme inhibitor; angiotensin II type I receptor blocker;
D O I
10.1097/00029330-200604020-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transforming growth factor (TGF) beta(1)-Smads signal plays an important role in cardiac remodeling following myocardial infarction (MI). In addition, both angiotensin converting enzyme inhibitor (ACEI) and angiotensin II type I receptor blocker (ARB) can effectively prevent left ventricular remodeling. The current study focused on whether the combination of ACEI and ARB is more beneficial for preventing ventricular remodeling and whether Smad proteins mediate this beneficial effect. Methods MI was induced by ligating the left anterior descending coronary artery in rats. Twenty-four hours after ligation, the survived rats were randomly divided into five groups and treated for 8 weeks: placebo group, ACEI group (benazepril 10 mg (.) kg(-1) (.) d(-1)), ARB group (irbesartan 50 mg (.) kg-(1 .) d(-1)), ACEI + ARB group (benazepril 10 mg (.) kg (.) d(-1) + irbesartan 50 mg (.) kg (.) d(-1)) and control group (sham-operated rats). After 8 weeks, we examined the following indexes: the ratio of ventricular weight to body weight,(VW/BW), left ventricular end diastolic dimension (LVDd), ejection fraction (EF), fractional shortening (FS), ratio of E-wave to A-wave velocity, collagen of noninfarcted zone, the mRNA expression of TGF beta(1), Smad 2, and Smad 3 by RT-PCR in noninfarcted zone, the protein expression of Smad 2 and Smad 3 in noninfarcted zone by Western blot. Results VW/BW significantly increased in the placebo groups compared with that in the control group (P < 0.01). This increase was limited in ACEI, ARB, and combined groups (P < 0.01 compared with placebo group). There was no significant difference among the three actively treated groups. Collagen was increased in placebo group (5.68 +/- 0.5)% compared with that in control group (P < 0.01). ACEI, ARB and combined treatment attenuated this increase of collagen [(4.3 +/- 0.5)%, (3.5 +/- 0.5)%, (3.2 +/- 0.4)%] in comparison with that in placebo group (P < 0.01 respectively). Combined treatment showed more significant effect on collagen deposition. EF and FS significantly decreased, LVDd and E/A significantly increased in placebo group compared with that in control group (P < 0.01 respectively). ACEI, ARB and combined treatment ameliorated these indexes (P < 0.01 compared with placebo group). The mRNA expression of TGF beta(1), Smad 2, and Smad 3 (0.700 +/- 0.045, 0.959 +/- 0.037 and 0.850 +/- 0.051) increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective in decreasing TGF beta(1) and Smad mRNA expression than ACEI treatment (P < 0.01). The expression of Smad 2 and Smad 3 protein increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective than ACEI alone (P < 0.01). Conclusions TGF beta(1)-Smads signal activation is correlated with ventricular remodeling following MI. ACEI and ARB treatment prevents ventricular remodeling by inhibiting expression of Smad 2 and Smad 3.. ARB and combined treatment are more effective than ACEI alone.
引用
收藏
页码:649 / 655
页数:7
相关论文
共 50 条
  • [2] Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection
    Hou, Fan Fan
    Zhou, Qiu Gen
    NEPHROLOGY, 2010, 15 : 57 - 60
  • [3] Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure
    Struckman, DR
    Rivey, MP
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (02) : 242 - 248
  • [4] Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
    Zhang, Chao
    Zhong, Jun
    Chen, Wei-Xiang
    Zhang, Xu-Yang
    Li, Yu-Hong
    Zhou, Teng-Yuan
    Zou, Yong-Jie
    Lan, Chuan
    Li, Lan
    Lai, Zhao-Pan
    Feng, Hua
    Hu, Rong
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 355 - 363
  • [5] Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor
    Sleight, Peter
    JOURNAL OF HYPERTENSION, 2009, 27 : S23 - S29
  • [6] Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin h receptor blocker therapy in heart failure
    Yasumura, Y
    Miyatake, K
    Okamoto, H
    Miyauchi, T
    Kawana, M
    Tsutamoto, T
    Kitakaze, M
    Matsubara, H
    Takaoka, H
    Anzai, T
    Himeno, H
    Yokoyama, H
    Yokoya, K
    Shintani, U
    Hashimoto, K
    Koretsune, Y
    Nakamura, Y
    Imai, K
    Maruyama, S
    Masaoka, Y
    Sekiya, M
    Shiraki, T
    Shinohara, H
    Ozono, K
    Matsuoka, T
    Miyao, Y
    Nomura, F
    CIRCULATION JOURNAL, 2004, 68 (04) : 361 - 366
  • [7] Successful treatment of severe hypertension with the combination of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker
    Tanemoto, M
    Abe, T
    Obara, N
    Abe, M
    Satoh, F
    Ito, S
    HYPERTENSION RESEARCH, 2003, 26 (10) : 863 - 868
  • [8] Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?
    Chen, Ching-Chu
    Chiang, An-Na
    Hsieh, Min-Huang
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 90 (02) : E25 - E26
  • [9] Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis
    Ujiie, Y
    Hirosaka, A
    Mitsugi, M
    Ohwada, T
    Igarashi, M
    Kijima, M
    Komatsu, N
    Hisa, S
    Abe, Y
    Tsuda, T
    Yaoita, H
    Maehara, K
    Maruyama, Y
    INTERNATIONAL HEART JOURNAL, 2006, 47 (02) : 173 - 184
  • [10] Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy
    Watanabe, K
    Juan, W
    Narasimman, G
    Ma, ML
    Inoue, M
    Saito, Y
    Wahed, MI
    Nakazawa, M
    Hasegawa, G
    Naito, M
    Tachikawa, H
    Tanabe, N
    Kodama, M
    Aizawa, Y
    Yamamoto, T
    Yamaguchi, K
    Takahashi, T
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 41 : S93 - S97